- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06291766
Gestational Diabetes After Gastric Bypass Surgery
The Impact of Continous Glucose Monitoring on Pregnancy Outcome, in Women With Gestational Diabetes and a History of Gastric Bypass Surgery.
The goal of this trial is to compare different means of glucose monitoring in women with gestational diabetes and a history of gastric bypass surgery.
The main question it aims to answer is:
How does continous glucose monitoring impact the treatment and affect pregnancy outcome in these women.
Participants will be randomized to either continous glucose monitoring or regular capillary glucose measurements during the last trimester of their pregnancy. Researchers will compare the glucose measurement outcomes, the glucose lowering treatment given and pregnancy outcomes between groups.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The project aims to investigate gestational diabetes in women with a history of gastric bypass surgery (GBP). The investigators will analyse glucose levels by using continuous glucose measurement (GCM) or capillary glucose measurements and compare mean glucose values, treatment and the pregnancy outcome.
In Sweden the incidence of gestational diabetes is 2-5% of pregnancies, but the frequency varies greatly in different areas and in different ethnicities. The women with gestational diabetes have an increased risk of complications during pregnancy. The most acknowledged complications are large for gestational age infants (LGA), preeclampsia and caesarean section. The infants have a higher need for neonatal intensive care, due to the risk of hypoglycaemia, hypoxia and jaundice postpartum. Treating gestational diabetes and normalizing glucose values have been proven to reduce risks of unfavourable pregnancy outcome.
Gastric bypass surgery is a common treatment for obesity. The frequency of young women with gastric bypass surgery and concomitant gestational diabetes have increased. Many maternity care centres have started to use a 3-7 day screening for gestational diabetes, since the routine oral glucose toleration test (OGTT) is not recommended after GBP. It is previously shown that women with GBP have a decreased risk of GDM and LGA infants. However, there is an increased risk of small for gestational age (SGA). There is a lack of knowledge and guidelines regarding the optimal treatment of gestational diabetes in these women. How the glucose variability affects pregnancy outcome is poorly investigated. At Lund University Hospital, Region Skane, Sweden, the screening procedure used since 2012 for GDM-screening in women with GBP is a 3 day 7-point capillary glucose measurement. Approximately 25% of the pregnant women with GBP is diagnosed with GDM, using this method at Lund University Hospital.
In this project the investigators will randomize women with gestational diabetes and a history of gastric bypass (GDM-GBP) into two different groups in the last trimester of pregnancy. Both groups are given standard medical care, which includes visits to the Specialized Maternity Care Unit and weekly follow up by the diabetologist. The first group is given continuous glucose measurement (FreeStyle Libre3) and the other group is given standard medical care which includes 7-point capillary glucose measurement. With the CGM system it is possible to collect more comprehensive data regarding glucose values and variability. Previous studies have shown that women with gastric bypass surgery have an earlier than normal postprandial glucose excursion and are more prone to later postprandial hypoglycaemia. During this study, the physician as well as the patient can observe the early glucose excursion after meals and measure time in target, time above target and time below target. Large for gestational age and accelerated growth of the infant is supposed to be due to high glucose values and a high proportion of Time above target. The increased risk of SGA infants in these women is hypothesized to be due to a large proportion of time below target. However, this theory is not sufficiently investigated and it is not known if the use of CGM can help to reduce the risk of weight deviation in the infants.
The investigators want to examine if new technique in glucose measurement can contribute to more favourable pregnancy outcome in women with gestational diabetes and a history of GDM. The main question is if the use of CGM affect pregnancy outcome. The secondary outcomes includes glucose variability and the use of different treatment approaches in GDM in this group of women.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ulrika Moll, MD, PhD
- Phone Number: +46733307170
- Email: ulrika.moll@skane.se
Study Locations
-
-
-
Lund, Sweden, 221 85
- Recruiting
- Region Skåne
-
Contact:
- Ulrika Moll, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Understands written and spoken Swedish
- Previous Gastric Bypass surgery
- Diagnosed with gestational diabetes according to our local criteria
- Planned follow up at the Specialized Maternity Ward at Skane University Hospital
- Understands the use of CGM and is willing to use the system
- Have signed informed consent
Exclusion Criteria:
- Other kinds of bariatric surgery
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Continous glucose measurement
Use of FreeStyle Libre 3, with Libre Link app and Glooko app for measurement and review of glucose measurements.
|
The use of FreeStyle Libre 3 sensors and Libre Link app and Glooko app for analysing glucose control in pregnancy
|
No Intervention: Capillary glucose measurement
Standard care, including capillary glucose measurements and Glooko app for review of glucose measurements.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Pregnancy Outcome
Time Frame: During delivery and postpartum (measured up to 5 days postpartum)
|
ANY: Caesarian section (Y/N), instrumental delivery (Y/N), preeclampsia (Y/N), premature birth before week 37 (Y/N), Macrosomia (>4000g) (Y/N), Large for gestational age infant (Y/N), small for gestational age infant (Y/N), shoulder dystocia (Y/N), neonatal hypoglycemia (Y/N) (<4 hours after birth: <1.4 mmol/L; 4 to <24 hours after birth: <1.9 mmol/L; 24 to <48 hours after birth: <2.8 mmol/L, ≥48 hours after birth: 3.3 mmol/L
|
During delivery and postpartum (measured up to 5 days postpartum)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glucose values
Time Frame: Gestational week 28-42
|
Mean/median glucose values (mmol/l)
|
Gestational week 28-42
|
Glucose values
Time Frame: Gestational week 28-42
|
Glucose variability (SD)
|
Gestational week 28-42
|
Glucose values
Time Frame: Gestational week 28-42
|
% Time in Target (3,5-7,8 mmol/l)
|
Gestational week 28-42
|
Glucose values
Time Frame: Gestational week 28-42
|
% Time below target
|
Gestational week 28-42
|
Glucose values
Time Frame: Gestational week 28-42
|
% Time above target
|
Gestational week 28-42
|
Pharmacological treatment
Time Frame: Gestational week 28-42
|
The use of insulin (Y/N)
|
Gestational week 28-42
|
Pharmacological treatment
Time Frame: Gestational week 28-42
|
the dose of insulin (IE)
|
Gestational week 28-42
|
Pharmacological treatment
Time Frame: Gestational week 28-42
|
the use of Metformin (Y/N)
|
Gestational week 28-42
|
Pharmacological treatment
Time Frame: Gestational week 28-42
|
the dose of metformin (g/day)
|
Gestational week 28-42
|
Birthweight
Time Frame: at the day of birth
|
birth weight of infant (g)
|
at the day of birth
|
Week of delivery
Time Frame: exact day (ie 28+0 to 42+6)
|
gestational week
|
exact day (ie 28+0 to 42+6)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ulrika Moll, MD, PhD, Region Skåne
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-05498-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes, Gestational
-
IRCCS Burlo GarofoloCompletedGestational Diabetes | Gestational Diabetes Mellitus | Pregnancy-Induced Diabetes | Diabetes Mellitus, Gestational | Diabetes, Pregnancy InducedIsrael, Italy, Netherlands, Slovenia, Sri Lanka
-
UPECLIN HC FM Botucatu UnespCompletedGestational Diabetes Mellitus | Pregestational Diabetes Mellitus | Mild Gestational HyperglycemiaBrazil
-
University of Texas Southwestern Medical CenterCompletedMild Gestational DiabetesUnited States
-
Royal College of Surgeons, IrelandHealth Research Board, IrelandUnknownPre-Gestational Diabetes
-
University of Colorado, DenverKaiser PermanenteCompletedGestational Diabetes MellitusUnited States
-
Intermountain Health Care, Inc.Withdrawn
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Baylor College of MedicineRecruitingGestational Diabetes MellitusUnited States
-
Joslin Diabetes CenterRoche DiagnosticsCompletedGestational Diabetes MellitusUnited States
-
Ludwig-Maximilians - University of MunichGerman Federal Ministry of Education and Research; Helmholtz Zentrum MünchenCompletedGestational Diabetes MellitusGermany
Clinical Trials on FreeStyle Libre 2, continous glucose monitoring
-
Nanjing First Hospital, Nanjing Medical UniversityUnknown
-
Jessa HospitalUnknownFlash Glucose Monitoring | Skin ReactionsBelgium
-
Abbott Diabetes CareCompleted
-
Shanghai General Hospital, Shanghai Jiao Tong University...UnknownDiabetes Mellitus, Type 2 | Flash Glucose MonitoringChina
-
Abbott Diabetes CareCompleted
-
Jessa HospitalUnknownMetabolic Control | Flash Glucose MonitoringBelgium
-
Abbott Diabetes CareCompleted
-
Abbott Diabetes CareCompleted